Atea Pharmaceuticals, Inc.AVIRNASDAQ
Loading
Cost of Revenue Over TimeContracting
Percentile Rank29
3Y CAGR-54.3%
5Y CAGR-31.0%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
-54.3%/yr
vs +678.3%/yr prior
5Y CAGR
-31.0%/yr
Recent deceleration
Acceleration
-732.6pp
Decelerating
Percentile
P29
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $5.96M | -92.8% |
| 2024 | $83.37M | +18.9% |
| 2023 | $70.09M | +12.3% |
| 2022 | $62.39M | -62.7% |
| 2021 | $167.21M | +339.7% |
| 2020 | $38.02M | +223564.7% |
| 2019 | $17000.00 | 0.0% |
| 2018 | $17000.00 | - |